Abstract: The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and/or the neurological and/or non-neurological sequelae thereof.

Abstract: Systems and methods for identifying subjects as having latent or primary herpesvirus infections and/or determining the time since the subject was exposed to or infected with a herpesvirus using machine learning algorithms are disclosed. An example method includes detecting in a bodily fluid sample from a subject a set of anti-virus antibody features and generating an input vector that includes data indicative of the anti-virus antibody features of the subject. The method also includes applying the input vector to a trained machine learning algorithm that is configured to generate an assigned classification to the subject. The assigned classification is one of a plurality of potential classifications of the machine learning algorithm.

Abstract: The present disclosure relates to anti-HSV (herpes simplex virus) antibodies comprising an Fc region having at least one modification or mutation that confers enhanced effector function and/or improved binding to viral Fc receptor (vFcR) and uses of such antibodies for preventing or ameliorating the effects of a neonatal HSV infection.

Abstract: Provided herein are compositions and methods for increasing transduction efficiency of cells (e.g., immune cells) with a viral vector by incubating said cells with one or more agents (e.g., AKT inhibitors and stains such as rosuvastatin) that increase transduction efficiency of cells.

Abstract: Directed evolution using yeast display was employed to isolate novel NKp30 variants that bind to B7H6 with higher affinity compared to the native receptor but retain its fast association and dissociation profile. Two variants, CC3 and CC5, were expressed as soluble Fc-fusion proteins and CARs containing CD28 and CD3? intracellular domains. These Fc fusion protein forms of NKp30 and its variants were better able to bind tumor cells expressing low levels of B7H6 than TZ47, and exhibited improved in vitro tumor cell killing relative to NKp30. Also, CAR T cells expressing the engineered variants produced unique cytokine signatures in response to multiple tumor types expressing B7H6 compared to both NKp30 and TZ47. These findings suggest that natural CAR receptors can be fine-tuned to produce more desirable signaling outputs while maintaining evolutionary advantages in ligand recognition relative to scFvs.

Abstract: The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and/or the neurological and/or non-neurological sequelae thereof.